FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3036140021> ?p ?o ?g. }

• W3036140021 endingPage "494" @default.
• W3036140021 startingPage "484" @default.
• W3036140021 abstract "Abstract Objectives To investigate the association of extremes in bodyweight (EBW) and outcomes in patients with acute venous thromboembolism (VTE). Recurrent VTE, major bleeding, and clinically relevant non‐major bleeding were compared between patients with bodyweight <60 kg, 60‐120 kg, and >120 kg. Methods Consecutive patients enrolled in the Mayo Clinic VTE Registry (03/28/2013‐8/31/2019) with acute VTE were followed prospectively. Patient status was assessed in person, by mailing a written questionnaire, or by a scripted phone interview. Results Among 2577 patients with weight ranging from 27.0 kg to 263.2 kg, 2123 (82%) had a bodyweight between 60 and 120 kg, 223 (8.7%) had bodyweight < 60 kg, and 230 (8.9%) had bodyweight >120 kg. Patients with bodyweight <60 kg treated with DOACs had higher 3‐ and 6‐month incidence of major bleeding compared to the bodyweight 60‐120kg group (4.4% vs 1.1%, P = .03, and 4.4% vs 1.4%, P = .05, respectively). Patients with bodyweight >120 kg and cancer on rivaroxaban had higher VTE recurrence compared to bodyweight 60‐120kg group ( P = .01). Conclusions Treatment of acute VTE is associated with a higher incidence of bleeding in patients with bodyweight <60 kg. A higher VTE recurrence rate occurred only in cancer patients with bodyweight >120 kg on rivaroxaban." @default.
• W3036140021 created "2020-06-25" @default.
• W3036140021 creator A5000523251 @default.
• W3036140021 creator A5017032740 @default.
• W3036140021 creator A5027269984 @default.
• W3036140021 creator A5037829121 @default.
• W3036140021 creator A5050586204 @default.
• W3036140021 creator A5060027910 @default.
• W3036140021 creator A5060617809 @default.
• W3036140021 creator A5075120531 @default.
• W3036140021 creator A5079076674 @default.
• W3036140021 creator A5086294602 @default.
• W3036140021 creator A5089993641 @default.
• W3036140021 creator A5090624109 @default.
• W3036140021 date "2020-07-27" @default.
• W3036140021 modified "2023-10-01" @default.
• W3036140021 title "Effectiveness and safety of apixaban and rivaroxaban for acute venous thromboembolism therapy in patients with extremes in bodyweight" @default.
• W3036140021 cites W2028512903 @default.
• W3036140021 cites W2035010389 @default.
• W3036140021 cites W2057179512 @default.
• W3036140021 cites W2071869524 @default.
• W3036140021 cites W2074947904 @default.
• W3036140021 cites W2075101732 @default.
• W3036140021 cites W2075359369 @default.
• W3036140021 cites W2115787552 @default.
• W3036140021 cites W2130199362 @default.
• W3036140021 cites W2130340163 @default.
• W3036140021 cites W2139785591 @default.
• W3036140021 cites W2166402206 @default.
• W3036140021 cites W2311379003 @default.
• W3036140021 cites W2337286163 @default.
• W3036140021 cites W2514950920 @default.
• W3036140021 cites W2519636314 @default.
• W3036140021 cites W2557845780 @default.
• W3036140021 cites W2595086780 @default.
• W3036140021 cites W2735376054 @default.
• W3036140021 cites W2755764073 @default.
• W3036140021 cites W2914247996 @default.
• W3036140021 cites W2946668006 @default.
• W3036140021 cites W2989714602 @default.
• W3036140021 doi "https://doi.org/10.1111/ejh.13471" @default.
• W3036140021 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32557773" @default.
• W3036140021 hasPublicationYear "2020" @default.
• W3036140021 type Work @default.
• W3036140021 sameAs 3036140021 @default.
• W3036140021 citedByCount "15" @default.
• W3036140021 countsByYear W30361400212021 @default.
• W3036140021 countsByYear W30361400212022 @default.
• W3036140021 countsByYear W30361400212023 @default.
• W3036140021 crossrefType "journal-article" @default.
• W3036140021 hasAuthorship W3036140021A5000523251 @default.
• W3036140021 hasAuthorship W3036140021A5017032740 @default.
• W3036140021 hasAuthorship W3036140021A5027269984 @default.
• W3036140021 hasAuthorship W3036140021A5037829121 @default.
• W3036140021 hasAuthorship W3036140021A5050586204 @default.
• W3036140021 hasAuthorship W3036140021A5060027910 @default.
• W3036140021 hasAuthorship W3036140021A5060617809 @default.
• W3036140021 hasAuthorship W3036140021A5075120531 @default.
• W3036140021 hasAuthorship W3036140021A5079076674 @default.
• W3036140021 hasAuthorship W3036140021A5086294602 @default.
• W3036140021 hasAuthorship W3036140021A5089993641 @default.
• W3036140021 hasAuthorship W3036140021A5090624109 @default.
• W3036140021 hasConcept C120665830 @default.
• W3036140021 hasConcept C121332964 @default.
• W3036140021 hasConcept C126322002 @default.
• W3036140021 hasConcept C2776301958 @default.
• W3036140021 hasConcept C2778661090 @default.
• W3036140021 hasConcept C2779161974 @default.
• W3036140021 hasConcept C2780638905 @default.
• W3036140021 hasConcept C2780868729 @default.
• W3036140021 hasConcept C2991741193 @default.
• W3036140021 hasConcept C61511704 @default.
• W3036140021 hasConcept C71924100 @default.
• W3036140021 hasConceptScore W3036140021C120665830 @default.
• W3036140021 hasConceptScore W3036140021C121332964 @default.
• W3036140021 hasConceptScore W3036140021C126322002 @default.
• W3036140021 hasConceptScore W3036140021C2776301958 @default.
• W3036140021 hasConceptScore W3036140021C2778661090 @default.
• W3036140021 hasConceptScore W3036140021C2779161974 @default.
• W3036140021 hasConceptScore W3036140021C2780638905 @default.
• W3036140021 hasConceptScore W3036140021C2780868729 @default.
• W3036140021 hasConceptScore W3036140021C2991741193 @default.
• W3036140021 hasConceptScore W3036140021C61511704 @default.
• W3036140021 hasConceptScore W3036140021C71924100 @default.
• W3036140021 hasFunder F4320306143 @default.
• W3036140021 hasIssue "4" @default.
• W3036140021 hasLocation W30361400211 @default.
• W3036140021 hasOpenAccess W3036140021 @default.
• W3036140021 hasPrimaryLocation W30361400211 @default.
• W3036140021 hasRelatedWork W1956559559 @default.
• W3036140021 hasRelatedWork W2498074933 @default.
• W3036140021 hasRelatedWork W2519928292 @default.
• W3036140021 hasRelatedWork W2603244127 @default.
• W3036140021 hasRelatedWork W2766681386 @default.
• W3036140021 hasRelatedWork W2924757266 @default.
• W3036140021 hasRelatedWork W2945764188 @default.
• W3036140021 hasRelatedWork W2990341591 @default.
• W3036140021 hasRelatedWork W3210936862 @default.

• next